Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

Evidence-Based Medicine

Volumn 15, Issue 3, 2010, Pages 69-70

  Harman, S Mitchell ^a  

^a Kronos Longevity Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; PLACEBO; PROGESTERONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HAZARD RATIO; HEART PROTECTION; HORMONAL THERAPY; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MENOPAUSE; NOTE; PATIENT COMPLIANCE; POSTMENOPAUSE; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77953782971     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1079     Document Type: Note

References (21)

1. The Writing Group for the WHI Trials. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33.
2. Manson JE, Hsia J, Johnson KC, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
3. Naftolin F, Taylor HS, Karas R, et al.; The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-501.
4. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7.
5. Brinton EA, Hodis HN, Merriam GR, et al. Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab 2008;19:206-12.
6. Harman SM, Brinton EA. Biphasic effects of hormone treatment on risk of cardiovascular disease: resolving the paradox in postmenopausal women. Menopausal Med 2009;17:S5-S8.
7. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. (Pubitemid 38489892)
8. Hsia J, Langer RD, Manson JE, et al.; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65.
9. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA 1983;249:903-6.
10. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9. (Pubitemid 17081015)
11. Wolf PH, Madans JH, Finucane FF, et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
12. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8.
13. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756-62.
14. Ettinger B, Friedman GD, Bush T, et al. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12. (Pubitemid 26015941)
15. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
16. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41. (Pubitemid 32003509)
17. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
18. NHLBI. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. National Institutes of Health, National Heart, Lung, and Blood Institute; 2006. p. 10.
19. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med 2001;135:1-8. (Pubitemid 32619277)
20. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766-79.
21. Chilvers CE, Knibb RC, Armstrong SJ, et al. Post menopausal hormone replacement therapy and risk of acute myocardial infarction-a case control study of women in the East Midlands, UK. Eur Heart J 2003;24:2197-205.